Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

The Future of the Proteomics Market 2019-2024 - Drug Discovery Expected to Hold a Significant Market Share - ResearchAndMarkets.com

May 23, 2019

DUBLIN--(BUSINESS WIRE)--May 23, 2019--

The “Proteomics Market - Growth, Trends, and Forecast (2019 - 2024)” report has been added to ResearchAndMarkets.com’s offering.

The global proteomics market is expected to witness a CAGR of 15.3% during the forecast period. Certain factors driving the market growth include rising demand for personalized medicine, increasing R&D expenditure and government funding for proteomics, and technological advancements.

These major drivers will continue to drive the biopharmaceutical industry’s pursuit of blockbuster drugs and the recent technological advances in the studies of genes and proteins. Alliances are becoming increasingly important in this field because it is challenging for companies to find all the necessary expertise to cover all activities involved in proteomics.

For example, many companies working with mass spectrometry and both the manufacturers and end-user labs are collaborating with protein chip-related companies. Increased demand for personalized medicines and increased R&D in proteomics are also driving factors for the market. However, the market is constrained by strict regulatory norms and the high cost of the instruments.

Drug Discovery is Expected to Hold a Significant Market Share in the Application Type

The identification of potential new drugs for the treatment of disease has been considered one of the most promising developments in the study of human genes and proteins. This depends on genome and proteome information for the identification of proteins, associated with a disease, which can then be used as targets for new drugs by computer software.

Preclinical stages in the process of drug discovery need a multitude of genetic and biochemical assays in order to characterize the effects of drug candidates on cellular systems as well as model organisms.

Almost every large pharmaceutical company now has proteomics-oriented biotech or academic partner or has started its own proteomics division. The general applications of proteomics in the drug industry include identification of efficacy and of toxicity biomarkers from readily accessible biological fluids, target identification and validation, and investigations into mechanisms of drug action or toxicity.

North America Dominates the Market and is Expected to Do the Same During the Forecast Period

In North America, antibody-drug conjugates and protein therapeutics play a significant role in the treatment and diagnosis of diseases. This is a continuously evolving field with extensive research on novel and innovative next-generation therapeutics. More than a hundred modified therapeutic proteins are approved for clinical use in the region.

Hundreds of protein therapeutics are in clinical trials for the treatment of cancer, immune disorders, infections, age-related diseases, and many other conditions. Besides, research on proteomics is at the highest in countries like the United States.

Competitive Landscape

The global proteomics market is highly competitive and consists of a number of major players. Companies like Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., Bruker Corporation, Danaher Corporation, GE Healthcare, Merck KGaA, Promega Corporation, Thermo Fisher Scientific, Inc., and Waters Corporation, among others, hold the substantial share in the proteomics market.

Key Topics Covered


1.1 Study Deliverables

1.2 Study Assumptions

1.3 Scope of the Study




4.1 Market Overview

4.2 Market Drivers

4.2.1 Rising Demand for Personalized Medicine

4.2.2 Increasing R&D Expenditure and Government Funding for Proteomics

4.2.3 Technological Advancements

4.3 Market Restraints

4.3.1 High Cost of Instruments

4.4 Porter’s Five Forces Analysis


5.1 Instrumentation Technology

5.1.1 Spectroscopy

5.1.2 Chromatography

5.1.3 Electrophoresis

5.1.4 Protein Microarrays

5.1.5 X-Ray Crystallography

5.1.6 Other Instrumentation Technologies

5.2 Services and Software

5.2.1 Core Proteomics Services

5.2.2 Bioinformatics Software and Services

5.3 Reagents

5.4 Application

5.4.1 Clinical Diagnostics

5.4.2 Drug Discovery

5.4.3 Other Applications

5.5 Geography

5.5.1 North America US Canada Mexico

5.5.2 Europe Germany UK France Italy Spain Rest of Europe

5.5.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific

5.5.4 Middle East & Africa GCC South Africa Rest of Middle East & Africa

5.5.5 South America Brazil Argentina Rest of South America


6.1 Company Profiles

6.1.1 Agilent Technologies Inc.

6.1.2 Bio-Rad Laboratories Inc.

6.1.3 Bruker Corporation

6.1.4 Danaher Corporation

6.1.5 GE Healthcare

6.1.6 Merck KGaA

6.1.7 Promega Corporation

6.1.8 Thermo Fisher Scientific Inc.

6.1.9 Waters Corporation


For more information about this report visit https://www.researchandmarkets.com/r/4wrai9

View source version on businesswire.com:https://www.businesswire.com/news/home/20190523005662/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Proteomics



SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 05/23/2019 01:11 PM/DISC: 05/23/2019 01:11 PM


All contents © copyright 2019 The Associated Press.All rights reserved.